Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

NCT07693751 is registered in ClinicalTrials.gov with SOTIO Biotech a.s. as lead sponsor.

NCT NCT07693751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07693751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
Lead sponsor
SOTIO Biotech a.s.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 12, 2026
Completion date
July 4, 2028
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (locally advanced or metastatic)